Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

Table 1 Demographic data (primary analysis set, n = 229)

	n	Results
Male gender, n (%)	229	132 (57.6)
Age (yr)	229
Mean (SD)	229	66.2 (11.5)
≥ 75, n (%)	229	68 (29.7)
Cancer other than metastatic colorectal cancer, n (%)	228	20 (8.8)
Duration since diagnosis of primary disease (yr), mean (SD)	226	2.9 (2.3)
Duration since diagnosis of metastatic disease (yr), mean (SD)	227	2.0 (1.5)
Metastatic sites, n (%)
Liver	229	170 (74.2)
Lung	229	92 (40.2)
Peritoneum	229	38 (16.6)
Lymph nodes	229	59 (25.8)
Bone	229	10 (4.4)
Other	229	29 (12.7)
BRAF genotyping performed, n (%)	225	70 (31.1)
If performed, BRAF genotyping
Non-mutated BRAF	70	62 (88.6)
Mutated BRAF	70	5 (7.1)
BRAF not assessable	70	3 (4.3)
Previous radiotherapy treatment (any cancer), n (%)	227	62 (27.3)
Previous adjuvant chemotherapya, n (%)	227	101 (44.5)
Previous chemotherapy for metastatic diseaseb, n (%)	229	207 (90.4)
Total treatment duration, weeks, mean (SD)
Line 1	207	26.3 (21.9)
Line 2	165	23.0 (20.5)
Line 3	97	19.9 (17.1)
Line 4	24	19.9 (17.6)
Previous radiotherapy for metastatic disease, n (%)		30 (13.1)
Abdominal lymph nodes	218	5 (26.3)
Pelvic	221	10 (45.5)
Other	221	18 (81.8)

^aMost frequent chemotherapy protocols (n = 99): LV5FU2/oxaliplatin FOLFOX (n = 42, 42.4%). FOLFIRI/bevacizumab (n = 9, 9.1%), LV5FU2 (n = 6, 6.1%), FOLFOX/bevacizumab (n = 5, 5.1%);

^bMost frequent chemotherapy protocols for lines 1 to 4, respectively: LV5FU2/oxaliplatin FOLFOX (22.2%, 13.3%, 8.2%, 16.7%), FOLFIRI/bevacizumab (28.0%, 18.2%, 23.7%, 0%); for lines 5 to 8 (n = 11, 6, 3,1): LV5FU2/oxaliplatin (27.3%, 0%, 33.3%, 0%). BRAF: Serine/threonine-protein kinase B-Raf; FOLFIRI: Folinic acid, fluorouracil and irinotecan; FOLFOX: Folinic acid, fluorouracil and oxaliplatin.